PreciseDx is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis. Combining AI with our patented Morphology Feature Array (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/21/24 | $20,700,000 | Series B |
Eventide Asset Management GenHenn Capital LabCorp Quest Diagnostics | undisclosed |
